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We have previously shown the existence of migra-
tory hematopoietic stem cells in adult solid organs. 
This study demonstrates that granulocyte colony-
stimulating factor (G-CSF) and lisofylline, a phospha-
tidic acid inhibitor that suppresses hematopoiesis-in-
hibiting cytokines, can enhance the engraitment of 
organ-based hematopoietic stem cells. When synge-
neic heart grafts or liver nonparenchymal cells were 
transplanted into lethally irradiated (9.5 Gy) Lewis 
rats, complete hematopoietic reconstitution and ani-
mal survival were significantly improved by treating 
the recipient with G-CSF or, to a lesser extent, with 
lisofylline. Pretreatment of hepatic nonparenchymal 
cell donors with G-CSF, but not lisofylline, also re-
sulted in striking improvement of recipient survival 
which was associated with an augmented subpopula-
tion of donor stem cells. The results suggest that these 
drugs can be used to enhance the chimerism that we 
postulate to be the basis of organ allograft acceptance. 
Recent evidence (summarized in [1]) suggests that passen-
ger leukocytes migrate after organ transplantation and pro-
duce persistent multilineage chimerism, which is essential 
for sustained survival of the allografts. Because the recipro-
cal immune modulation of the coexisting cell populations 
cancels the risk of graft-versus-host disease in noncytoab-
lated recipients (the two-way paradigm LID, the donor con-
tribution to the resulting donor-recipient dialogue can be 
bolstered safely by the perioperative administration of unal-
tered donor bone marrow (2). 
As an alternative to donor leukocyte infusion, or to in-
crease its efficiency, we have suggested that the organ recip-
ient's chimerism might be promoted by posttransplant ad-
ministration of granulocyte colony-stimulating factor (G-
CSF*). granulocyte-macrophage colony-stimulating factor 
(GM-CSF). and other hematolymphopoietic growth factors (1, 
:n that are already known from clinical experience to facili-
tate bone marrow engraftment in cytoablated patients (4, 5). 
This possibility is supported by the results reported herein. 
comparing the "rescue" efficiency of lisofylline and G-CSF in 
t.he same isogeneic rat model of supralethal irradiation pre-
viously used to demonstrate the presence of pluripotent stem 
cells in normal rat livers and hearts (61. 
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Lisofylline (a gift from Cell Therapeutics, Inc., Seattle, 
WA) is a phosphatidic acid inhibitor (7) that has been postu-
lated to facilitate bone marrow engraftment by suppressing 
hematopoiesis-inhibiting cytokines (e.g., tumor necrosis fac-
tor-a, transforming growth factor-/3, macrophage inhibitory 
protein I-a, and platelet factor 4) that are typically released 
to activation stimuli in the posttransplant period, while not 
altering levels or activities of the myeloid progenitor cell-
promoting cytokines G-CSF and GM-CSF (8). 
G-CSF is made principally by endothelial cells, monocytes, 
and fibroblasts. Although its main biologic consequences 
have been described as increased proliferation and differen-
tiation of neutrophils from committed progenitor cells (9), it 
actually has these effects on stem cells and all derivative 
lineages (10-12). For our experiments, rhG-CSF (Neupogen) 
was purchased from Amgen (Thousand Oaks, CAl. 
Eight- to ten-week-old Lewis (RT1',LEW) rats weighing 
200-250 g were purchased from Harlan Sprague Dawley (In-
dianapolis, IN) and kept in a laminar flow, specific-pathogen-
free environment. Most of the experiments were performed 
with male donors and recipients. However, by performing male 
-4 female transplantation in separate nonsurvival experiments, 
we determined (as in our earlier reports [6]) whether the hema-
topoietic reconstitution was with donor cells as opposed to re-
covery of the cytoablated recipient stem cells. The tissues and 
organs of the hematopoietically reconstituted recipient were 
studied with polymerase chain reaction and Southern hybrid-
ization, using rat Y-chromosome (sex-determining region Y)-
specific primers (6). 
The transplants used for testing in the irradiated recipi-
ents were bone marrow cells, nonparenchymal cells (NPC) 
isolated from donor livers, and intact hearts. Bone marrow 
cells with >95% viability (trypan blue) were harvested from 
the tibias and femurs and processed in RPMI 1640 medium 
supplemented with 25 mM HEPES, 2 mM L-glutamine, 50 
Dlml penicillin. and 50 I-lg/ml streptomycin (6). Whole hearts 
were removed after exsanguination of the nonnal or pre-
treated donor under methoxyflurane anesthesia. flushed 
clean with intra-artenal chilled lactated Ringer's solution, 
and transplanted heterotopically to the abdominal location 
16), Hepatic NPC were purified from donor livers with the 
collagenase method ( 13). 
The livers were tlushed in Situ to an asanguinous state 
through a portal vein cannula with 120 ml of Leibovitz's L-15 
medium containmg :5 mM EGTA. 10 mM HEPES. and 50 
ILglml gentamicin. An additional infusion was then given of 
:;00 ml of L-15 medium l'nnched with 0.05<:0 collagenase 
I tvpe B. Boehringer \lannheim. \lannheim, Germanvi. 
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0.005% trypsin inhibitor (Sigma, St. Louis, Mo), 2.5% fetal 
bovine serum (FBS), and 50 /Lg/ml gentamicin. The liver was 
removed to a petri dish, and parenchymal cells and NPC 
were liberated from the connective tissue by careful raking of 
the liver with scissors and by gentle shaking. The initial cell 
suspension was filtered through nylon mesh, and a crude 
fraction of NPC was obtained by differential centrifugation 
(four times at 60xg for 3 min). 
The number of migratory passenger leukocytes trans-
planted in the whole hearts was not known. The dose of 
0.5 x 106 bone marrow cells was previously shown to be inad-
equate for reconstitution. All of the hepatic NPC from single 
livers were given to individual recipients, with no attempt to 
compensate for the cell loss incurred during preparation. The 
yield from the 18 livers used in experimental groups 12-14 
was variable, with a mean:!:SD of 150.6:!:57.4 cells (Table 1) 
with >85% viability (trypan blue). The number of NPC was 
not significantly different than that in the livers from donors 
pretreated with lisofylline and G-CSF for use in groups 17 
and 18, respectively. The bone marrow and NPC suspensions 
were injected into the penile vein of the irradiated recipients. 
All 18 experimental groups were given 9.5 Gy of total body 
irradiation from a cesium source (Table 2). No treatment was 
given to group 1. In group 2, twice daily intraperitoneal 
lisofylline was given for 9 days (day -1 to day 7), and in 
group 3, rhG-CSF was injected subcutaneously twice daily 
(Table 2) at doses previously standardized by Foster et a1. 
(14). Four to eight hours after irradiation, groups 4-14 were 
given heterotopic hearts or infusions of a cell suspension 
(bone marrow or NPC), with or without one or the other test 
drugs (Table 2). In groups 15-18 (Table 2), the effect of 
pretreating donors for 3 days (day - 3 to day -1) with either 
lisofylline or G-CSF was determined; no posttransplant ther-
apy was given (Table 2). 
The principal end point in all 18 groups was survival of the 
irradiated animals. Because no animal died after 40 days in 
this or in our earlier study (6), survival for this long was 
considered permanent. As in our earlier study (6), the 9.5-Gy 
irradiation caused 100% mortality (group 1, Table 2). This 
was not affected by treatment with lisofylline (group 2). How-
ever, half of the animals treated only with G-CSF recovered 
( grou p 3). Because they did not receive any kind of trans-
plant, their full reconstitution (see Table 3) obviously was 
from their own residual stern cells. 
G-CSF strikingly potentiated the rescue effect of heart 
transplantation, allowing 83.3% reconstitution and survival 
I group 8) compared with only occasional survival (14.3%) 
with heart transplantation alone I group 4)' Similarly, sur-
vival after heart transplantation was increased to 62.5% and 
75'7c with the administration of 200 and 150 mg/kg/day liso-
fyUine I groups 5 and 6), respectively, but not with doses of 
100 mg/kg/day (group 71. Two additional female animals 
were studied 30 days after rescue with a male heart plus 
T.\BLE 1. Total number of NPC in normal and in lisofylline- and 
G-CSF-treated livers 
I )onor I ~1gDlrpp I n 
----
L'ntreated 112. 13. 14) 
Liso(vlline pre-treated 
171 
E~-Cpc prp-treated 118) 
18 
Total NPCiliver 1 x 10';) 
150.6 ~ 57.4 
104.4 ~ 19.3 
~ 10.6 ::c :l6.7 
lisofylline (as in group 6). Only about 1% of the DNA in 
spleen was of male origin, indicating ultimate recovery of 
cytoablated recipient stern cells. 
Both test drugs also increased survival when given to the 
irradiated recipient after transplantation of a suboptimal 
dose of bone marrow. Survival was increased from 0 (group 9) 
to 16.7% with lisofylline (group 10) and to 80% with G-CSF 
(group 11). 
Similar results were obtained when the test agents were 
combined with transplantation of hepatic NPC: from 0% us-
ing NPC only (group 12) to 50% with the addition of lisofyl-
line (group 13) and to 66.7% with G-CSF (group 14). In one 
special male -> female NPC experiment under the lisofylline 
treatment conditions of group 13, approximately 1% of the 
splenic DNA was male at 100 days. This indicated self-recon-
stitution, in contrast to our previous finding after transplan-
tation of the whole liver without drug treatment, following 
which fully reconstitution was primarily by donor stem cells 
(6). 
The superior therapeutic qualities of G-CSF versus lisofyl-
line were evident in the lineage characteristics in peripheral 
blood 45-55 days after rescue with liver NPC (Table 3). 
Monoclonal antibodies were used against R7.3 (af3-T cell 
receptor), W3/25 (CD4), OX8 (CD8), OX33 (B cells), 3,2.3 
(NKR-P1), and ED1 (macrophages) (Sera-Lab, Crawley Down, 
UK). Animals given G-CSF plus NPC (group 14) had a profile 
similar to that in normal LEW rats and rats that self-reconsti-
tuted with the aid of G-CSF alone (group 3). In contrast, one 
survivor with lisofylline plus NPC (group 13) had evidence of 
delayed or incomplete hematolymphopoietic reconstitution. 
The inability of NPC isolated from single livers to rescue 
any animal (group 12, Table 2) unless either lisofylline or 
G-CSF was added may have been due simply to loss of, or 
damage to, the donor leukocytes during their purification. 
This was suggested by the ability to restore the rescue capa-
bility of the hepatic NPC to 100% survival by donor pretreat-
ment with G-CSF (Table 2, group 18) but not with lisofylline 
(group 17), a difference that also was present but not statis-
tically significant in hearts procured from similarly pre-
treated donors (Table 2, group 15 vs. group 16). Because the 
number of hepatic NPC was not dramatically altered by 
donor pretreatment, the relative effect of lisofylline and G-
CSF on hematopoietic precursor cells in the liver was esti-
mated by determining colony-forming unites) (CFU), using 
the fibrin clot culture system with modifications (Table 4). 
The crude extract ofliver NPC was passed through a nylon 
wool column at 37°C; nonadherent cells were left for the 
assay. These cells were resuspended in complete lscove's 
modified Dulbecco's medium supplemented with 10 mM 
HE PES. 50 /Lglml gentamicin, 8 mM L-glutamine. and 
5x 10-:'; M 2-mercaptoethanol. They were further mixed with 
2% pokeweed mitogen (Sigma)-stimulated. LEW splenocyte-
conditioned medium. 20'7c FBS, l'k bovine serum albumin, 
1.0 mg/ml bovine fibrinogen solution (Sigma), 1.0 U/ml bo-
vine thrombin solution (Sigma I. and 0.5 mM NG-monometh-
yl-L-arginine-HOAC (Cyclo:lPSS Biochemical Co., Salt Lake 
City, UT) in a tinal concentration of 1 x lOo/mi. 
A total suspension volume of 1.0 ml was plated in the 
middle of a tiO-mm Parmanox dish (Nunc, Naperville. ILl, 
and 1 ml of complete Iscove's modified Dulbecco's medium 
with 20t;} FBS and I', bovine serum albumin was added 
;lround the clot. The cultures were kept for 6 days in a fully 
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TABLE 2. Improved survival of lethally irradiated (9.5 Gy) animals of syngeneic heart graft, liver NPC, or bone marrow infusion with 
lisofylline and G-CSF treatment" 
Group Organ/cells Treatment Survival (days) Median 40-Day survival n (days) rate (%) 
Recipient treatment 
1 None None 10 10, 10, 11, 11, 12, 12, 13, 13, 13, 13 12.0 0 
2 None Lisofylline 7 11, 11, 12, 13, 13, 15, 16 13.0 0 
3 None G-CSF 6 9, 9, 9, > 100 x 3 >54.5 50 
4 Heart None 7 12,12,13,14,17,25, >100 14.0 14.3 
5 Heart Lisofylline 8 12, 18, 30, > 100 x 5 >100 62.5 
6 Heart Lisofylline (75) 8 12,18, >100 x 6 >100 75.0 
7 Heart Lisofylline (50) 7 12, 13, 13, 13, 17, 17, > 100 13.0 14.3 
8 Heart G-CSF 6 13, >100 x 5 >100 83.3 
9 BM None 5 10, 10, 10, 12, 14 10.0 0 
10 BM Lisofylline 6 12,13,13,14,38, >100 13.5 16.7 
11 BM G-CSF 5 16, >100 x 4 >100 80.0 
12 Liver NPC None 6 10, 13, 13, 13, 15, 15 13.0 0 
13 Liver NPC Lisofylline 6 15,17,19, >100 x 3 >59.5 50 
14 Liver NPC G-CSF 6 13,18, >100 x 4 >100 66.7 
Donor treatment 
15 Heart Lisofylline 6 10, 11, 11, 13, 13, 18 12.0 0 
16 Heart G-CSF 6 12,15,17,17, >100 x 2 17.0 33.3 
17 Liver NPC Lisofylline 7 11, 12, 12, 12, 12, 12, 13 12.0 0 
18 Liver NPC G-CSF 7 >100 x 7 >100 100 
" Recipient doses were 100 mglkg lisofylline intraperitoneally every 12 hr on days -1 to 7 except in group 6 (75 mglkg) and group 7 (50 
mglkgl, and 100 f.Lglkg rhG-CSF subcutaneously every 12 hr on days -1 to 7. Donor pretreatment was 100 mg/kg lisofylline intraperitoneally 
every 12 hr on days -3 to -1, and 100 f.Lglkg rhG-CSF subcutaneously every 12 hr on days -3 to -1. Group 3 versus groups 8, 11, or 14: 
no significant difference (Mann-Whitney U test). 
TABLE 3. Hematopoietic recovery in lethally irradiated (9.5 Gy) animals of syngeneic liver NPC infusion with lisofylline and G-CSF 
treatment (45-55 days after radiation and transplantation) 
a/3-TCR+ (R7.3) CD4 (W3/25) CDB <OX8) B cells (OX33) NK (3.2.3) Monocytest Group Organ/cells Treatment" n (%) (%) (%) (%) (%) macrophage (EDl)(%) 
Recipient treatment 
Nonnal LEW 5 71.7::: 8.3 62.7::: 4.0 25.1 ::: 3.5 14.0::: 4.9 .'3.4 ::: 0.6 10.4 ::: 4.2 
3 None G-CSF 2 78.2 65.6 30.0 16.5 4.9 16.5 
66.8 69.8 27.4 14.6 3.1 11.7 
13 Liver NPC Lisofylline 1 46.5 80.2 12.8 1.3 4.6 NT 
14 Liver NPC G-CSF 2 65.0 63.2 29.2 18.8 2.1 17.6 
68.3 64.2 28.0 14.8 2.5 12.7 
Donor treatment 
18 Liver NPC G-CSF 2 69.4 67.5 21.9 4.5 3.3 NT 
71.9 67.2 20.0 10.8 3.2 NT 
" Recipient doses were 100 mg/kg lisofylline mtraperitoneally every 12 hr on days -1 to 7, and 100 ILg/kg rhG-CSF subcutaneously every 
12 hr on days -1 to 7. Donor pretreatment was 100 iJ.g/kg rhG-CSF subcutaneously every 12 hr on days -3 to -1. 
humidified atmosphere with 5'7r CO:! in air at 37°C. Clusters 
riO -50 cells/aggregate) and colonies (>50 cells/aggregate) 
were quantitated as CFU-C counts. The striking augmenta-
tion of CFU by G-CSF and the surpnsing absence of a liso-
fylline effect are evident in Table 4. 
It might be argued that the foregoing differences in the 
rpconstitution by transplantation of the whole liver versus its 
:--.1PC could be due to removal of a collaborative engraftment 
functIOn of the hepatocytes or parenchymal cells of other 
organs In the second instance. e.g., lymphopoietic growth 
factors known to be secreted bv hepatocytes. as discussed by 
:'lurase et al. (3). Our study does not exclude this possibility. 
The administration of G-CSF to the hepatic NPC recipient 
(group 14. Table 2) and especially to the donor (group 18. 
Table 2) allowed survival of irradiated animals at the same 
rate as reported previously with the whole liver (6). Recon-
stitution with a suboptimal supply of donor pluripotent cells 
apparently was predominantly by recovery of the recipient 
stem cells. which was made possible by the "bridge" variably 
provided by transplanted stem cells. 
If. as with bone marrow transplantation. the quantity of 
stem cell engraftment is critical to successful transplantation 
of organs. the findings reported herem suggest that reCipient 
treatment wlth recombinant G-CSF. GM-CSF. c-kit ligand. 
• 
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TABLE 4. Frequency of CFU in liver NPC obtained from normal 
and lisofvlline- or G-CSF treated· donors 
-----
Donor n CFU·C/lO" cells" 
Untreated 4 7.9::': 3.9 
Lisofylline treated 2 4.5::': 3,1 
G-CSF treated 4 50.3::': 33.5° 
n Nylon wool nonadherent liver NPC. 
h P < 0.001 VS. untreated (unpaired Student's t test). 
the flt3 ligand (J5), and other hematolymphopoietic growth 
factors may constitute a therapeutic tool at least as powerful 
as (and not mutually exclusive of) the donor leukocyte aug-
mentation procedures currently under evaluation in organ 
recipients. Administration of G-CSF to liver transplant re-
cipients was recently reported by Foster et al. (16), who 
attributed improved patient and graft survival to buttressed 
neutrophil-dependent infectious defenses. However, we pos-
tulate that the benefits noted in patients (16), as well as the 
significant prolongation of heart allograft survival in other-
wise untreated rat recipients (14), was due primarily to aug-
mentation of spontaneous chimerism. 
REFERENCES 
1. Starzl TE, Demetris AJ. Murase N, Trucco M, Thomson AW, Rao 
AS. The lost chord: microchimerism. Immunol Today 1996; 17: 
577. 
2. Fontes P. Rao A. Demetris AJ, et al. Augmentation with bone 
marrow of donor leukocyte migration for kidney, liver, heart, and 
pancreas islet transplantation. Lancet 194; 344: 151. 
3. Murase N, Starzl TE, Tanabe M. et al. Variable chimerism. graft 
versus host disease. and tolerance after different kinds of cell 
and whole organ transplantation from Lewis to Brown-Norway 
rats, Transplantation 1995; 60: 158. 
4, Lieschke GJ, Burgess A W. Granulocyte colony-stimulating fac-
tor and bTfanulocyte-macrophage colony-stimulating factor. 
N Engl J Med 1992; 327: 99. 
5. Moore MAS. Clinical implications of positive and negative he-
matopoietic stem cell regulators. Blood 1991; 78: 1. 
6. Murase N, Starzl TE, Ve Q, et a1. Multilineage hematopoietic 
reconstitution of supralethally irradiated rats by syngeneic 
whole organ transplantation: with particular reference to the 
liver. Transplantation 1996; 61: 1. 
7. Clarke E. Rice GC. Weeks RS, et al. Lisofylline inhibits trans-
forming growth factor beta release and enhances trilineage he-
matopoietic recovery after 5-fluorouracil treatment in mice. Can-
cer Res 1996; 56: 105. 
8. Singer JW, Bursten 8L. Rice GC. Gordon wp. Bianco JA. Inhib-
itors of intracellular phosphatidic acid production: novel thera-
peutics with broad clinical applications. Exp Opin Invest Drugs 
1994; 3: 631. 
9. Bociek RG, Armitage JO. Hematopoietic growth factors. CA Can-
cer J Clin 1996; 46: 165. 
10. Uckun F, Souza L, Waddick KG, Wick M, Song CWo In vivo 
radioprotective effects of recombinant human granulocyte colo-
ny-stimulating factor in lethally irradiated mice. Blood 1990; 75: 
638. 
11. Tanikawa S. Nose M, Aoki Y. Tsuneoka K. Shikita M, Nara N. 
Effects of recombinant human granulocyte colony-stimulating 
factor on the hematologic recovery and survival of irradiated 
mice. Blood 1990; 76: 445. 
12. Schuening FG, Storb R, Goehle S, et a1. Effect of recombinant 
human granulocyte colony-stimulating factor on hematopoiesis 
of normal dogs and on hematopoietic recovery after otherwise 
lethal total body irradiation. Blood 1989; 74: 1308. 
13. Berry MN. Friend DS. High-yield preparation of isolated . rat 
liver parenchymal cells. J Cell BioI 1969; 43: 506. 
14, Foster PF, Kociss K, Shenn J. et al. Granulocyte colony stimu-
lating factor immunomodulation in the rat cardiac transplanta-
tion model. Transplantation 1996; 61: 1122. 
15. Lyman SD, James L, Bos TV, et al. Molecular cloning ofa ligand 
for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor 
for primitive hematopoietic cells. Cell 1993; 75: 1157. 
16. Foster PF, Mital D. Sankary HN. et al. The use of granulocyte 
colony stimulating factor \G-CSF) following liver transplanta-
tion. Transplantation 1995; 59: 1557. 
Received 3 December 1996. 
Accepted 20 February 1997. 
BIOPHYSICAL ASPECTS OF LIVER AERATION BY VASCULAR 
PERSUFFLATION WITH GASEOUS OXYGEN 
THOMAS MINOR,I,2 HILTRUD KLAUKE,1 BRIGI'ITE VOLL:\lAR,:J WOLF ISSELHARD,l AND 
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Backf!round, Venous systemic oxygen persufflation 
of the liver 1 i.e., gaseous insufflation of oxygen via the 
venous vascular system) has proven to be an effective 
tool for preventing anoxic tissue injury during ex-
tended time periods of ischemic preservation. It also 
lnstltutt' t',r Expenmentall'.ledicine. rniverslt~D of ('o!o/.,TJ1e, 
, .\ddrl'ss mrrespondence to: T. '.linor. lnst. f. Exp. :\!,'dicine. 
1'l\l\'t'rSl[\, o(Cologne, Robert Koch Str, 10.509:31 Colo/.,TJ1e. (;"rmanv 
InstJtult' ,.". ('Iinical and Expenm!'ntul ~urgeryK L'ni\,l'fSlIV of 
:":':1;lri:1Ild. 
allows for an improved recovery of the persufflated 
organ after orthotopic transplantation. 
Methods. Biophysical aspects of the persufflation 
technique with regard to persufflation pressure (9 
mmHg versus 18 mmHg) and oxygen concentration 
(pure oxygen versus air) in the persufflation gas were 
investigated in rat livers. using epi.illumination mi· 
croscopic detection of autofluorescence of NADH. 
which accumulates in anoxic tissue. 
Results. We demonstrated that a low-pressure per-
sufflation 19 mmHgJ is as sufficient as a higher pres-
